Unraveling Cannabidiol's Dual Modulatory Role in Schizophrenia: Network Pharmacology and In Vivo Validation of Neuroinflammatory and Behavioral Modulation Authors: Ying Wei, Xiang Liu, Shijun Lin, Zhiwei Jia, Lin Liu, Baiqiang Wang, Linchuan Liao, Xue Mei Published: 2025 ABSTRACT AbstractSchizophrenia (SCZ), a chronic psychiatric disorder, is characterized by cognitive impairment, hallucinations, and delusions, with current antipsychotic treatments offering limited efficacy and considerable side effects. Cannabidiol (CBD), a non-psychoactive compound from Cannabis sativa, has shown promise in treating neurological and psychiatric conditions, though its precise mechanisms in schizophrenia remain unclear. Using network pharmacology, this study predicts CBD’s targets and pathways in schizophrenia, highlighting LPS-induced neuroinflammation and implicating 5-HT1AR-MAPK signaling as one potential contributor. In vitro, CBD (10 mg/kg, i.p.) treatment significantly reduced pro-inflammatory cytokines (e.g., NO, IL-1β, IL-6, TNF-α) and modulated the 5HT1AR-MAPK pathway, including increased 5HT1AR expression and decreased MAPK/ERK1/2 phosphorylation (p < 0.05). In vivo, CBD alleviated SCZ-like symptoms in a ketamine-induced animal model, reducing anxiety in the open field (p < 0.01) and elevated plus maze tests (p < 0.01), improving spatial memory in the Y-maze (p < 0.01) and social behavior (p < 0.0001) after 5 consecutive days of treatment. Critically, we validated CBD’s central anti-inflammatory effects by demonstrating reduced pro-inflammatory cytokine levels in both plasma and brain tissues (p < 0.05). Further correlation analysis established a direct link between brain cytokine suppression and behavioral improvements, integrating in vitro findings from BV2 microglial cells with in vivo neuroinflammatory and behavioral outcomes.These findings suggest the potential therapeutic benefits of CBD for SCZ, though further research, particularly clinical trials, is required to validate its efficacy and establish it as a novel therapeutic strategy.Supplementary InformationThe online version contains supplementary material available at 10.1007/s12035-025-05608-8.Keywords: Cannabidiol, Schizophrenia therapy, Network pharmacology, Neuroinflammation, 5HT1AR-MAPK signaling pathway Introduction Schizophrenia (SCZ) is a chronic disorder affecting about 1% of the global population and is one of the leading causes of disability worldwide [1, 2]. It is characterized by negative symptoms (e.g., social withdrawal, blunted affect), positive symptoms (e.g., hallucinations, delusions), and cognitive deficits (e.g., impaired memory, executive function) [3, 4]. Approximately 30% of patients do not respond to current treatments targeting positive symptoms, and there are no effective therapies for negative or cognitive symptoms [5, 6]. Furthermore, a substantial proportion of patients experience symptomatic (psychotic) relapse after initial recovery (for example, around 80% within 5 years in a first-episode cohort), and discontinuation of antipsychotics increases relapse risk nearly fivefold. Together with the 20–50% who exhibit treatment resistance, this underscores the need for new therapeutic strategies [7, 8]. Despite advances in neuroimaging, which have provided insights into the underlying neurobiological mechanisms [9], current antipsychotic treatments are associated with significant side effects, such as sedation and akathisia/extrapyramidal symptoms, underscoring the importance of exploring novel drug candidates [6, 10, 11]. Therefore, the need to explore novel drug candidates and pharmacological mechanisms is of utmost importance. Compelling evidence increasingly suggests that inflammation may be linked to SCZ [12, 13], especially neuroinflammation [14, 15]. A range of converging evidence implies that microglia and astrocytes within the central nervous system (CNS) are key immune/glial cells implicated in SCZ-related pathology and symptoms [16–23], are associated with SCZ-related symptoms. Moreover, evidence from ketamine-based animal models and human studies links neuroinflammation to specific SCZ-relevant behaviors, including anxiety-like and social (negative) behaviors, positive-symptom surrogates such as hyperlocomotion, and cognitive impairments in spatial recognition memory [24–28]. Cannabidiol (CBD), a non-intoxicating compound found in Cannabis sativa, has emerged as a promising remedy in the therapeutic landscape for a wide array of neuropsychiatric conditions. It is a non-addictive component of cannabis that is different from tetrahydrocannabinol (THC, the main psychotomimetic constituent of cannabis), and its neuroprotective properties may mitigate brain damage related to neurodegenerative and ischemic disorders [29, 30]. As early as the 1970 s, several studies have shown CBD’s ability to improve symptoms similar to SCZ in THC-intoxicated individuals, and even in healthy volunteers [31, 32]. This emphasizes the potential antipsychotic activity of CBD. Furthermore, it was observed that CBD has a protective effect against THC-induced SCZ-related symptoms, such as delusions and hallucinations [33, 34]. In terms of anti-schizophrenic efficacy, several clinical trial studies have revealed that CBD can reduce psychotic symptoms in patients with schizophrenia similar or superior to the typical antipsychotic drugs such as haloperidol, amisulpride, etc. [35–37]. These observations were echoed in different animal models of SCZ. It is reported that CBD can improve core symptoms (e.g., prepulse inhibition of startle response deficits, stereotyped behavior, hyperlocomotion, anxiety, cognitive deficits) of experimental animal models of SCZ induced by N-methyl-D-aspartate receptor antagonists (MK-801 or ketamine) [38–42]. However, in these studies, CBD was co-administered with either MK-801 or ketamine, and while several studies have explored the anti-schizophrenic activities of CBD from the behavioral, neurochemical, protein molecules, epigenetic modifications or immune-cell perspective [39, 41, 43–49]. Although multiple mechanisms have been involved in the antipsychotic effects of CBD [45, 50], our study integrates network pharmacology with experimental validation to provide deeper insight into CBD’s molecular targets and signaling, highlighting neuroinflammation and implicating 5-HT1AR–MAPK signaling as one contributing pathway. To gain a deeper understanding of the molecular mechanism of the antipsychotic-like effects of CBD, we utilized an integrative approach combining cell signaling pathway and network pharmacology analysis. Network pharmacology applies biological network analyses to clarify mechanisms of drug action and the relationships among drug components, targets, and diseases [51]. This approach enables exploration of complex multicomponent-multitarget interactions. Using a comprehensive ‘disease-target-drug component’ network model, we aimed to investigate the molecular pathways involved in CBD’s effects. Building on this approach, we conductedin vitroexperiments using Brain Macrophage-2 (BV-2) cells and in vivo studies in a ketamine-induced SCZ model to validate these targets. This study aims to elucidate the molecular mechanisms underlying CBD’s effects and the pathways it modulates, offering a novel, integrative perspective on its therapeutic role in SCZ. By combining network pharmacology with experimental validation, we provide a comprehensive understanding of CBD’s potential in treating SCZ. While CBD’s anti-inflammatory properties have been explored in prior research, our study introduces a unique approach by utilizing network pharmacology to predict CBD’s molecular targets and pathways specific to SCZ. We identified LPS-induced neuroinflammation and point to 5-HT1AR-MAPK signaling as plausible contributors to CBD’s effects, areas not yet extensively characterized in SCZ. This integrative methodology allows us to connect these molecular pathways with both behavioral outcomes and neuroinflammatory markers, providing a holistic view of CBD’s actions. Our findings set the stage for future investigations into CBD as a potential transformative therapeutic intervention for SCZ. Results Network Pharmacology Predicting Potential Targets for the Antipsychotic-Like Effect of Cannabidiol A total of 156 targets of cannabidiol were identified by using DrugBank, SwissTargetPrediction, PharmMapper and STITCH. Moreover, 867 SCZ-related targets were screened from the GeneCards, OMIM, TTD, PharmGKB and GEO Database. To further uncover the potential pharmacological mechanisms of cannabidiol activity against SCZ, 31 predicted targets were selected by focusing on their overlaps (Fig. 1). Anticipating potential targets for the antipsychotic-like effect of cannabidiol Network Construction and Enrichment Analyses 31 predicted targets were inputted into the STRING database, and a protein–protein interaction network was constructed using a medium confidence cut-off (0.400). The network was visualized using the Cytoscape software. The network has 29 nodes and 92 edges (Fig. 2A). The central nodes were identified in this network using the MCODE plugin within filtering degree ≥ 9 as a criterion. The network analysis revealed that FAAH, ANXA1, OPRM1, CYP2D6, CYP3A4, HTR1A, CNR2, and GRM2 were the central nodes with a higher degree in the network (Fig. 2B). This suggests that these central genes may play a critical role in mediating the antipsychotic-like effect of cannabidiol. The 31 potential targets were further subjected to GO analysis and KEGG pathway enrichment to investigate the molecular mechanism underlying the effect of cannabidiol on SCZ. The outcomes of the GO analysis include biological process (BP), cell component (CC) and molecular function (MF) terms. In Fig. 2C, the top 10 enriched conditions in the BP, CC, and MF categories were presented as the outcomes of the GO analysis. The BP analysis indicated that the 31 targets were predominantly enriched in the multi-fatty acid metabolic process. The CC analysis revealed a noticeable enrichment of these targets in synapses, presynaptic membranes, and neuronal cell bodies. Furthermore, in the MF analysis, these targets were primarily enriched in categories such as molecule binding, oxidoreductase activity, neurotransmitter binding, and neurotransmitter receptor activity. The KEGG pathway enrichment analysis revealed that these 31 predicted targets contributed to 12 pathways (Fig. 2D). KEGG pathway analysis implicated neuroactive ligand-receptor interaction, serotonergic synapse, and calcium signaling among candidate mechanisms underlying CBD’s antipsychotic-like effects. Network construction and enrichment analyses of predicted targets and pathways associated with the antipsychotic-like effects of cannabidiol. (A) PPI network of 31 predicted cannabidiol targets, with 29 nodes and 92 edges, visualized using Cytoscape. (B) Central nodes identified using MCODE (degree ≥ 9), including FAAH, ANXA1, OPRM1, CYP2D6, CYP3A4, HTR1A, CNR2, and GRM2. (C) GO analysis of the 31 targets, highlighting enrichment in multi-fatty acid metabolic process (BP), synapses and neuronal cell bodies (CC), and molecule binding and neurotransmitter receptor activity (MF). (D) KEGG pathway enrichment revealing 12 key pathways, including neuroactive ligand-receptor interaction, serotonergic synapse, and calcium signaling CBD Preventing Neuroinflammation in BV2 Cells Induced by LPS Cell Viability Since BV2 is a murine microglial cell line, and microglia have been implicated in the pathogenesis of SCZ. Microglia are the resident immune cells in the brain, and their dysregulation has been linked to neuroinflammation, which is thought to play a role in SCZ [52, 53]. Here, the BV2 cell line was selected, and the viability of BV2 cells was assessed using the CCK-8 assay to determine the impact of varying doses of CBD. The CCK-8 assay was used firstly to determine the effects of different doses of CBD on the viability of BV2 cells. It was observed that each dose of CBD had a minimal effect on cell vitality [Fig. 3A, F (7, 16) = 1.481, p= 0.2428]. Subsequently, the effects of CBD (5, 10 and 50 µmol/L) and LPS (1 µg/mL) on cell viability were detected. Co-treatment with CBD and LPS showed little effect on cell viability [Fig. 3B, F (4,10) = 1.362 p = 0.114]. Therefore, three CBD concentrations (5, 10, and 50 μmol/L) were used for experiments targeting LPS-induced inflammation in BV2 cells. Effects of different CBD doses on BV2 cell viability and the impact of co-treatment with CBD and LPS. (A) BV2 cells were treated with increasing concentrations of CBD (0–100 μM) for 24 h. Cell viability was assessed using the CCK-8 assay. (B) BV2 cells were stimulated with LPS (1 μg/mL) for 24 h, either alone or in combination with various concentrations of CBD (5, 10, or 50 μM). Data are expressed as mean ± SD from three independent experiments. One-way ANOVA was used to analyze the differences between groups, and Tukey’s post-hoc test was employed to further assess pairwise comparisons. No significant changes in cell viability were observed with LPS treatment alone or in combination with CBD (p > 0.05) Protective Effect of CBD on Neuroinflammation Induced by LPS To investigate the potential anti-inflammatory effects of CBD on BV2 cells stimulated with LPS (1 mg/mL). ELISA assays were conducted to measure the levels of NO, IL-1β, IL-6, and TNF-α in order to assess the impact of CBD on inflammation. As is shown in Fig. 4, the levels of inflammatory mediators (NO, IL-1β, IL-6, and TNF-α) were found to be significantly higher in the LPS group compared to the control group (p < 0.0001). However, as the concentration of CBD increased, there was a notable decrease in the production of NO in comparison to the control group [Fig. 4A, F (4, 10) = 37.35, p < 0.0001]. The observed effects of CBD on the output of IL-1β [Fig. 4B, F (4, 10) = 19.22, p = 0.0001] and TNF-α [Fig. 4D, F (4, 10) = 30.77, p < 0.0001] were consistent with those of NO (Fig. 4B, D, p < 0.01). In contrast, pretreatment with 5 and 10 µmol/L CBD did not result in any significant changes in IL-6 levels. However, 50 µmol/L doses of CBD significantly reduced IL-6 levels [Fig. 4C, F (4, 10) = 19.22, p = 0.0001]. Accordingly, we used 10 µmol/L CBD for downstream signaling assays as the minimal effective, non-cytotoxic dose that consistently reduced LPS-induced NO, IL-1β, and TNF-α (while avoiding potential non-specific effects at 50 µM), enabling cleaner interrogation of 5-HT1AR–cAMP/MAPK pathways. Effects of different CBD doses on neuroinflammation mediators covering NO (A), IL-1β (B), IL-6 (C), and TNF-α (D). Data were analyzed using one-way ANOVA to assess differences between groups, followed by Dunnett's multiple comparisons test for pairwise comparisons. Statistical significance is indicated as follows: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 when compared to the control group; #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 when compared to the LPS-treated group CBD Prevented LPS-Induced Neuroinflammation, in Part via 5HT1AR-MAPK Signaling Pathway Network pharmacology studies have provided valuable insights into the potential mechanisms underlying the neuroprotective effects of CBD. As is shown in Fig. 2, it has suggested that CBD exerts its neuroprotective actions, at least in part, through modulation of the serotonergic synaptic signaling pathway. The 5-HT1AR, a subtype of serotonin receptor, plays a crucial role in regulating various physiological processes in the central nervous system [54, 55]. Activation of 5-HT1AR has been linked to several neuroprotective effects, including reduction of neuroinflammation, promotion of neuronal survival, and modulation of synaptic transmission [54, 56]. Therefore, targeting this receptor presents a promising avenue for investigating the potential therapeutic benefits of CBD. This led us to the identification of 5-HT1AR as one of the core targets involved in CBD’s neuroprotective effects. The molecular docking analysisdemonstrated that CBD interacts favorably with the 5HT1AR receptor, with a binding energy of −7.4 kcal/mol. Key interacting residues, including TYR-96, PHE-112, ILE-113, ASP-116, THR-200, and PHE-361, form stable interactions with CBD through hydrogen bonds and hydrophobic contacts (Fig. 5A). Molecular dynamics (MD) simulations further validated the stability of the CBD-5-HT1AR complex. The RMSD plot (Fig. 5B) showed that the complex remained stable over 100 ns, while the RMSF analysis (Fig. 5C) indicated limited flexibility of key binding site residues, supporting the robustness of the interaction. The radius of gyration (Fig. 5D) remained consistent throughout the simulation, reflecting the compactness and structural integrity of the protein–ligand complex. The free energy landscape (Fig. 5E) revealed a well-defined global energy minimum, suggesting the complex adopted a stable conformational state during the simulation. MM/PBSA binding free energy decomposition analysis (Fig. 5F, Table 1) indicated that van der Waals interactions (VDWAALS) contributed most significantly to the favorable total binding free energy, further confirming the stable and energetically favorable interaction between CBD and 5-HT1AR. Molecular docking, dynamics simulations, and energetic analysis of CBD binding to 5-HT1AR. (A) Molecular docking model illustrating the binding interaction between CBD (shown in purple) and the 5-HT1AR protein (shown in cyan cartoon representation). Key interacting residues (TYR-96, PHE-112, ILE-113, ASP-116, THR-200, PHE-361) are depicted as sticks, and hydrogen bonds are indicated by dashed lines. (B) Root Mean Square Deviation (RMSD) plot of the CBD–5-HT1AR complex over 100 ns of molecular dynamics simulation. (C) Root Mean Square Fluctuation (RMSF) plot showing the flexibility of each residue within the 5-HT1AR protein during the simulation. (D) Radius of gyration (Rg) plot of the CBD-5-HT1AR complex over 100 ns. (E) Free Energy Landscape (FEL) based on RMSD and radius of gyration, the global minimum energy basin is indicated by the deep blue region. The right panels show the corresponding 2D interaction map and the representative structure from the most stable cluster. (F) Binding free energy decomposition using MM/GBSA calculations. Contributions from van der Waals interactions (VDWAALS), electrostatic energy (ELE), polar solvation energy (EGB), and non-polar solvation energy (ESURF) are shown Table 1Binding free energy components (kcal/mol) of the protein–ligand complex calculated by MM-GBSA methodEnergy typeEnergy value(kcal/mol)△Evdw−44.46△Eele−0.99△EGB3.08△Esurf−6.24△EGas−45.45△Esolv−3.16△EBind−48.61△Evdw is the van der Waals energy, △Eele is the electrostatic energy; △EGB is the polar solvation energy; △Esurf is the non-polar solvation energy; △EGas is the gas phase free energy; △EGas = △Evdw + △Eele; △Esolv is the solvation energy; △Esolv = △EGB + △Esurf; △EBind is the overall binding free energy, △EBind = △EGas + △Esolv Binding free energy components (kcal/mol) of the protein–ligand complex calculated by MM-GBSA method △Evdw is the van der Waals energy, △Eele is the electrostatic energy; △EGB is the polar solvation energy; △Esurf is the non-polar solvation energy; △EGas is the gas phase free energy; △EGas = △Evdw + △Eele; △Esolv is the solvation energy; △Esolv = △EGB + △Esurf; △EBind is the overall binding free energy, △EBind = △EGas + △Esolv Building on these in silico findings, we next conducted a series ofin vitroexperiments to verify whether the predicted stable interaction between CBD and 5-HT1AR translates into functional and biological effects in cellular models. As is shown in Fig. 6, cell viability assays [Fig. 6A, F (4, 10) = 1.243e-010, p > 0.9999] confirmed that neither CBD nor the 5-HT1AR antagonist WAY-100635 (10 μM) exhibited cytotoxicity under the experimental conditions [57, 58]. Western blot analysis (Fig. 6B and C) [Fig. 6C, F (4, 10) = 74.88, p < 0.0001] further revealed that LPS treatment, both alone (p < 0.01) and in combination with the 5-HT1AR antagonist WAY-100635 (p < 0.0001), significantly downregulated 5-HT1AR expression. However, CBD treatment effectively prevented the reduction in 5-HT1AR expression caused by LPS (p < 0.001), suggesting that CBD protects the receptor from LPS-induced downregulation. The ELISA results (Fig. 6D-F) showed that CBD significantly attenuated LPS-induced increases in pro-inflammatory cytokines including IL-1β [Fig. 6D, F (4, 10) = 52.88, p < 0.0001], IL-6 [Fig. 6E, F (4, 10) = 59.22, p < 0.0001] and TNF-α [Fig. 6F, F (4, 10) = 74.88, p < 0.0001]. This reduction indicates that CBD’s anti-inflammatory effects are mediated through 5-HT1AR, notably, these anti-inflammatory effects were largely maintained in the presence of WAY-100635, indicating that they are not strictly dependent on 5-HT1AR. Given that 5-HT1AR activation is known to inhibit adenylyl cyclase and reduce intracellular cAMP levels, we next evaluated cAMP concentrations in BV2 cells to determine whether CBD functionally engages this signaling pathway. As in shown in Fig. 6G, CBD (10 μM) significantly reduced cAMP levels [Fig. 6G, F (5, 12) = 58.44, p < 0.0001], comparable to the classical 5-HT1AR agonist 8-OH-DPAT (10 μM) [59–61]. While pretreatment with the selective 5-HT1AR antagonist WAY-100635 (10 μM) abolished CBD-induced cAMP reduction, restoring cAMP to baseline levels, supporting 5-HT1AR involvement in the cAMP readout. Taken together, the data suggest that CBD interacts with and stabilizes 5-HT1AR and can signal through the 5-HT1AR-cAMP axis, while its suppression of pro-inflammatory cytokines likely also engages 5-HT1AR-independent mechanisms and pathway crosstalk (e.g., MAPK/ERK). These findings are consistent with CBD functioning as a modulator of 5-HT1AR-associated signaling rather than relying exclusively on this receptor [62]. As is shown in Fig. 7A and B, western blot analysis revealed that compared with the control group, LPS significantly reduced the expression of 5HT1AR protein [Fig. 7B, F (2, 6) = 62.26, p < 0.0001]. However, CBD intervention markedly attenuated LPS-induced 5-HT1AR downregulation (p < 0.0001), reinforcing its role in stabilizing receptor expression under neuroinflammatory conditions. In addition, since 5HT1AR is a serotonin receptor protein located upstream of the MAPK/ERK1/2 signaling pathway. Activation of 5HT1AR can inhibit the phosphorylation of downstream MAPK and ERK1/2 proteins. This is corroborated by the findings illustrated in Fig. 7C to E, where the phosphorylation of p38 [Fig. 7E, F (2, 6) = 66.96 p < 0.0001] and ERK1 [Fig. 7C, F (2, 6) = 76.44 p < 0.0001], ERK2 [Fig. 7D, F (2, 6) = 31.04, p = 0.0007] protein was inhibited in both LPS and CBD treated group (p < 0.01). Since the phosphorylation of p38 and MAPK/ERK1/2 is necessary for the activation of AP-1 and the subsequent regulation of inflammatory responses. As is shown in Fig. 7F, the transcription of the AP-1 protein was inhibited accordingly, which indicated the inhibiting the secretion of inflammatory mediators [Fig. 7F, F (2, 6) = 52.30, p = 0.0002]. Collectively, and together with the docking/cellular assays, these results indicate that CBD engages 5-HT1AR-linked pathways and converges on MAPK/ERK/AP-1 signaling. The interaction of CBD with 5-HT1AR in modulating LPS-induced inflammatory responses and cAMP generation in vitro. (A) Cell viability assay showing the effects of LPS (1 μg/mL), CBD (10 μM), and WAY-100635 (10 μM) on cell viability. (B) Western blot analysis of 5-HT1AR levels in cells treated with LPS, CBD, and WAY-100635, β-actin was used as loading control. (C) Densitometric quantification of 5-HT1AR protein expression normalized to β-actin. (D–F) ELISA measurement of pro-inflammatory cytokines IL-1β (D), IL-6 (E), and TNF-α (F) in the culture supernatant. (G) Measurement of intracellular cAMP levels in cells treated with combinations of CBD, 8-OH-DPAT, and WAY-100635. Data were normalized to β-actin and analyzed by one-way ANOVA, followed by Tukey’s multiple comparisons test. *, Compared to the control group, #, compared to the LPS group.+, compared to the LPS + CBD group; @, compared to the LPS + WAY −100635group; &,compared to the 8-OH-DPAT group; $,compared to the CBD group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; #p < 0.05, ##p < 0.01, ####p < 0.0001, ++++p < 0.0001. @p < 0.05, @@p < 0.01, @@@p < 0.001; &p < 0.05, &&&&p < 0.0001; $$$p < 0.0001. LPS = lipopolysaccharide (1 μg/mL), CBD = cannabidiol (10 μM), WAY = WAY-100635 (10 μM), 8-OH-DPAT (10 μM) CBD intervention reverses LPS-induced downregulation of 5HT1AR and associated proteins expression. (A) Representative Western blot analysis showing protein levels of 5-HT1AR, ERK1/2, phosphorylated ERK1/2 (P-ERK1/2), p38, phosphorylated p38 (P-p38), and Ap-1, with GAPDH as a loading control, in cells treated with LPS and/or CBD. (B) Quantification of 5-HT1AR expression normalized to GAPDH. (C, D) Relative expression of phosphorylated ERK1 (C) and ERK2 (D) normalized to total ERK1/2 protein. (E) Quantification of phosphorylated p38 relative to total p38. (F) Relative expression of Ap-1 protein normalized to GAPDH. Data were analyzed by one-way ANOVA, followed by Tukey’s multiple comparisons test. *, Compared to the control group; #, compared to LPS treated group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ##p < 0.01, ###p < 0.001, and ####p < 0.0001 CBD Alleviates Ketamine-Induced SCZ-Like Behavior and Inflammation CBD Alleviates Ketamine-Induced SCZ-like Behavior To investigate the effect of CBD on SCZ-like behavior induced by continuous ketamine administration in mice, we assessed positive, negative, and cognitive domains using the OFT, EPM, Y-maze tests and social interaction tests (Sociability and Social Memory). The results are shown in Fig. 8. In the OFT, one-way variance analysis showed significant differences in motor activity among different groups [Fig. 8A, F (2, 12) = 9.344, p = 0.0036]. Dunnett's multiple test analysis showed that ketamine significantly increased the motor activity of mice compared with the control group (p < 0.01), and CBD mitigated increased activity (p < 0.01). This suggests that CBD can counteract ketamine-induced hyperlocomotion, which is commonly used as an index of positive symptomatology. Effects of CBD on schizophrenia-like behavior were evaluated in the open field test (OFT). (A), elevated plus-maze (EPM) test (B, C), and cognitive function was assessed using the Y-maze test (D), and the three-chamber test for sociability and social memory (E, F). Data were expressed as mean ± SD, with n = 5 per group. Statistical analysis was performed using one-way ANOVA, with significant differences indicated as **p < 0.01 and ***p < 0.001 compared to the control group, and ##p < 0.01 compared to the ketamine group For the assessment of anxiety-like behavior, we used the EPM. The time spent in the open arms was decreased significantly in the ketamine group compared with the control group [Fig. 8B, F (2, 12) = 14.79, p < 0.001], while CBD-treated animals showed significant improvement, spending more time in the open arms (p < 0.01). Although the number of entries into the open arms was not significantly different among the groups, there was a trend towards increased entries in the CBD-treated group compared to the ketamine group (p = 0.0826) (Fig. 8C), suggesting that CBD alleviates ketamine-induced anxiety. We assessed cognitive function using the Y-maze test, where a significant difference in spontaneous alternation was observed between the groups [Fig. 8D, F (2, 12) = 10.86, p = 0.0020]. Dunnett’s multiple comparisons test showed that ketamine-treated mice had a significantly reduced alternation rate, whereas CBD treatment improved cognitive performance, as evidenced by a significant increase in spontaneous alternation (p < 0.01), suggesting that CBD mitigates ketamine-induced cognitive deficits. Furthermore, social interaction was assessed using the three-chamber test, which evaluates sociability and social memory. In the Sociability test, CBD-treated mice exhibited a significantly higher preference for the social stimulus compared to the ketamine-only group, as shown by their preference score [Fig. 8E, F (2, 12) = 44.81 p < 0.0001]. In the Social Memory test, ketamine-treated mice showed a significant reduction in preference for the novel social stimulus (p < 0.01). While the CBD treatment did not show a significant increase in preference, there was a trend towards improvement (p = 0.0697) compared to the ketamine-only group [Fig. 8F, F (2, 12) = 7.386, p = 0.0081]. These results suggest that CBD can improve social behavior and memory, which are key components of the negative symptoms of SCZ, though further studies are needed to confirm the full extent of its effects. CBD Mitigates Ketamine-Induced inflammation A range of converging evidence implies that SCZ is associated with the inflammatory response [63, 64]. As shown in Fig. 9, ketamine administration significantly increased pro-inflammatory cytokines, including IFN-γ [F (2, 12) = 8.550 p = 0.0049], IL-1β [F (2, 12) = 49.38 p < 0.0001], IL-2 [F (2, 12) = 4.921 p = 0.0275], IL-5 [F (2, 12) = 2.647 p = 0.1116], IL-12p70 [F (2, 12) = 29.42 p < 0.0001], and TNF-α [F (2, 12) = 35.99 p < 0.0001], reflecting a strong inflammatory response. CBD treatment notably reduced these cytokine levels, especially IL-1β and TNF-α, highlighting CBD’s potent anti-inflammatory effects. In addition, ketamine reduced the anti-inflammatory cytokine IL-10, but CBD restored IL-10 levels [F (2, 12) = 16.99 p = 0.0003], indicating CBD’s role in rebalancing immune responses and promoting an anti-inflammatory state. Effects of CBD on ketamine-induced plasma cytokine levels. IFN-γ (A), IL-1β (B), IL-2 (C), IL-5 (D), IL-10 (E), IL-12p70 (F), and TNF-α (G) were measured by ELISA in control, ketamine-treated, and ketamine plus CBD-treated groups. Data were presented as n = 5 per group. Statistical analysis was performed using one-way ANOVA, followed with Tukey’s multiple comparisons test. Statistical significance was indicated as *p < 0.05, **p < 0.01, ***p < 0.001 compared to the control group, and #p < 0.05, ###p < 0.001 compared to the ketamine group CBD Modulates Brain Inflammation and Enhances Behavioral Outcomes Through the 5HT1AR-MAPK Pathway: Correlation Analysis of Cytokine Levels and Behavior To directly link CBD’s modulation of the 5HT1AR-MAPK signaling pathway with the observed behavioral improvements, we conducted a correlation analysis between the levels of pro-inflammatory cytokines in the brain tissue and the corresponding behavioral outcomes, including social interaction, anxiety-like behavior, and cognitive function. Figure 10A-C shows the levels of IL-1β, IL-6, and TNF-α in brain tissue. In the Ketamine group, the brain levels of IL-1β (Fig. 10A, p < 0.05) and IL-6 (Fig. 10B, p < 0.05) were significantly increased compared to the Control group, consistent with neuroinflammation associated with ketamine-induced schizophrenia-like symptoms. Importantly, treatment with CBD in the Ketamine + CBD group reversed these increases in IL-1β (Fig. 10A, p < 0.05) and IL-6 (Fig. 10B, p < 0.05), indicating CBD’s ability to modulate central neuroinflammatory cytokines. Although the change in TNF-α levels (Fig. 10C) did not reach statistical significance (p = 0.0639), a trend towards reduced TNF-α levels was observed in the Ketamine + CBD group compared to the Ketamine group. Effects of CBD on ketamine-induced brain cytokine levels. IL-1β (A), IL-6 (B), and TNF-α (C) were measured by ELISA in brain tissue from control, ketamine-treated, and CBD-treated groups. Data are presented as mean ± SD (n = 5 per group). Statistical analysis was performed using one-way ANOVA, followed by Dunnett’s multiple comparisons test. Statistical significance was indicated as *p < 0.05 compared to the control group, and #p < 0.05 compared to the ketamine group. (D) Correlation heatmap showing the relationship between brain cytokines levels (TNF-α, IL-1β, IL-6) and behavioral outcomes, including total distance, sociality, spontaneous alternation, social memory, and time spent in open arms. The heatmap depicts significant correlations (p < 0.05) with red and blue indicating positive and negative correlations, respectively Additionally, a correlation heatmap illustrating the relationship between brain cytokine levels (TNF-α, IL-1β, and IL-6) and behavioral outcomes is provided (Fig. 10D and Supplementary Table S1). A significant positive correlation was observed between the levels of TNF-α, IL-1β, and IL-6 with the total distance traveled, while a significant negative correlation was observed between the levels of TNF-α, IL-1β, and IL-6 with the sociability and spontaneous alternation. Interestingly, the level of IL-6 was negative correlated with social memory, while the level of IL-1β was negative correlated with time spent in open arms. These results suggest that the cytokine levels in the brain are associated with the behavioral improvements observed after CBD treatment, reinforcing the mechanistic role of CBD’s modulation of the 5HT1AR-MAPK signaling pathway in enhancing behavior. Discussion SCZ is a complex psychiatric disorder characterized by symptoms such as hallucinations, delusions, and cognitive impairments. Despite the availability of antipsychotic medications, their efficacy is limited and often accompanied by severe side effects [10, 11]. Therefore, there is a growing interest in exploring alternative treatment strategies. One such effective approach involves utilizing CBD, a non-psychoactive substance extracted from the cannabis plant. Research findings from preclinical and clinical studies suggest that CBD holds potential therapeutic benefits for a range of neuropsychiatric conditions, including SCZ [36, 65, 66]. Our findings align with clinical trials demonstrating CBD’s efficacy in reducing psychotic symptoms, supporting its potential as an adjunctive therapy for SCZ. CBD’s neuroprotective and anti-inflammatory properties offer a promising avenue for addressing both the positive and cognitive symptoms associated with SCZ, a condition that currently has limited therapeutic options. Several clinical studies have highlighted CBD’s role in alleviating psychotic symptoms and improving cognitive function, often with fewer side effects compared to traditional antipsychotics. For instance, a multicenter randomized controlled trial by Leweke et al. found that CBD was effective in reducing the severity of psychotic symptoms in patients with SCZ, showing results comparable to first-line antipsychotics like amisulpride, yet with a more favorable side-effect profile [35]. Similarly, another study by Boggs et al. confirmed that CBD not only alleviated positive symptoms but also improved cognitive performance in patients with SCZ from our preclinical models, particularly the reduction of neuroinflammation and improvements in cognitive and anxiety-related behaviors, suggest that CBD may serve as an effective adjunct to existing antipsychotic treatments [67]. This aligns with the growing body of evidence that neuroinflammation plays a central role in the pathophysiology of SCZ. CBD’s 5HT1AR-MAPK signaling pathway may help mitigate this inflammation, offering a dual benefit of both symptom relief and neuroprotection, which is crucial as the disease progresses. Furthermore, given the promise shown by CBD in alleviating treatment-resistant SCZ, future studies should focus on evaluating its role in these difficult-to-treat patient populations. While current antipsychotics often fail to fully address treatment-resistant symptoms, CBD has shown potential to enhance therapeutic outcomes in clinical trials. In particular, combining CBD with conventional therapies could provide a more comprehensive approach by targeting both the neuroinflammatory pathways and the serotoninergic system, which are both implicated in the pathophysiology of SCZ. Additionally, CBD’s neuroprotective effects, as observed in our study, could have significant implications for early-stage psychosis. Neuroprotective therapies are urgently needed to prevent or delay the onset of chronic psychiatric conditions, and CBD could potentially fill this gap. Exploring CBD as an early intervention in patients at high risk for SCZ or during the prodromal phase of psychosis could provide valuable insights into its preventive capabilities [46–50]. The results not only underscore the potential of CBD as a therapeutic agent for SCZ but also highlight its promise as a neuroprotective adjunct in both treatment-resistant and early-phase SCZ. This mechanistic foundation is rooted in our integrative approach, which constructed a comprehensive network of protein–protein interactions to map CBD’s engagement with SCZ-associated pathways. Specifically, we identified the LPS-induced neuroinflammation pathway and the 5HT1AR-MAPK signaling cascade as contributing pathways modulated by CBD, suggesting a dual modulatory role that could address both neuroinflammatory and serotonergic dysregulation in SCZ. This approach provides a novel, systems-level understanding of CBD’s multifaceted actions, moving beyond the traditional single-target focus that characterizes most pharmacological studies. Notably, molecular docking analysis revealed that CBD interacts with the 5HT1AR receptor and plays a functional role in suppressing neuroinflammatory cascades and cAMP generation. This interaction likely alters the receptor's conformational state, preventing the activation of downstream signaling pathways, such as MAPK and ERK1/2, which are key players in the pathophysiology of SCZ [68]. This novel finding reinforces the concept of serotonin signaling as a potential therapeutic target for CBD, aligning with existing studies that have explored this mechanism in both depression and SCZ. Previous research has demonstrated that CBD’s modulation of the 5HT1AR receptor may contribute to the reduction of psychotic symptoms and depressive behaviors, highlighting the therapeutic potential of CBD through the serotonin system in these psychiatric conditions [69–72]. The network pharmacology approach employed in our study enabled us to identify neuroinflammation as a central feature of SCZ. Neuroinflammation has been strongly implicated in the development of SCZ, with evidence from both animal and human studies highlighting its significant role in the disorder’s pathophysiology [73, 74]. This aligns with our experimental findings: in vitro, CBD significantly attenuated LPS-induced neuroinflammation in BV2 microglia by reducing pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6), while in vivo, CBD administration in a ketamine-induced SCZ model mirrored these effects, suppressing plasma levels of TNF-α, IL-1β, IL-12p70, and IFN-γ. Critically, the parallel reductions in TNF-α and IL-1β across both models underscore CBD’s capacity to disrupt neuroinflammatory cascades at multiple levels, a mechanism further supported by its restoration of anti-inflammatory IL-10, promoting immune homeostasis. Notably, elevated TNF-α levels have been consistently linked to the exacerbation of psychotic symptoms, and the marked reduction in TNF-α following CBD treatment suggests that CBD may have direct therapeutic effects on psychosis, contributing to symptom improvement in SCZ. IL-10 is a crucial anti-inflammatory cytokine that plays a protective role in regulating the immune response and promoting neuroprotection. The restoration of IL-10 levels by CBD suggests that CBD not only reduces harmful inflammation but may also actively support the brain’s natural protective mechanisms, promoting a homeostatic immune balance. These findings extend prior reports of CBD’s immunomodulatory effects and highlight its potential to address a core pathological feature of SCZ that remains largely untouched by current antipsychotics [75, 76]. One of the key contributions of this work is the integration of in vitro and in vivo data. Our BV2 cell culture experiments revealed that CBD can reduce the levels of pro-inflammatory cytokines, such as IL-1β, IL-6, and TNF-α, in BV2 microglial cells, supporting its anti-inflammatory properties. Importantly, these in vitro findings were mirrored in the in vivo ketamine model of SCZ, where CBD treatment led to a significant reduction in brain cytokines. The correlation analysis between cytokines levels and behavioral improvements (e.g., social interaction, anxiety-like behavior, and cognitive function) further substantiated the role of central inflammation in mediating CBD’s therapeutic effects. These data underscore the 5HT1AR-MAPK pathway as a critical signaling axis through which CBD modulates neuroinflammation, ultimately leading to improvements in SCZ-related behaviors. Beyond its immunomodulatory properties, CBD’s therapeutic efficacy in SCZ stems from its unique interaction with the serotonergic system. Reports suggest that CBD enhances anandamide signaling and alleviates psychotic symptoms associated with SCZ [35]. It appears to act in the dorsal striatum to enhance haloperidol-induced catalepsy by interacting with postsynaptic 5-HT1A receptors [77]. Molecular docking and functional assays revealed that CBD binds to 5-HT1AR with high affinity (−7.4 kcal/mol), selectively inhibiting downstream MAPK/ERK1/2 phosphorylation and AP-1 activation. This interaction aligns with behavioral evidence: CBD attenuated ketamine-induced cognitive deficits in the Y-maze test and anxiety-like behaviors in the EPM/OFT, effects replicated in studies where 5-HT1AR activation rescued synaptic plasticity and reduced aggression in socially isolated mice [78, 79]. Specifically, another study highlighted that it attenuates behavioral changes in a SCZ mice model via 5-HT1A, rather than CB1 and CB2 receptors [43], highlighting the 5HT1AR-MAPK signaling pathway as a promising target for CBD’s antipsychotic effects and underscoring the need for innovative research into these targeted mechanisms. Both the in vivo and in vitro experiments suggested that targeting inflammation is a crucial aspect in the treatment of SCZ. Here, we are the first to point out that the 5HT1AR-MAPK signaling pathway emerged as a potential specific target of CBD’s therapeutic effects. This highlights the potential interplay between CBD’s anti-inflammatory and serotonergic effects and provide insights into the potential therapeutic mechanisms of CBD in SCZ.Importantly, our study provides the first evidence that the 5HT1AR-MAPK signaling pathway may serve as a specific target for CBD’s therapeutic effects in SCZ. This discovery highlights the potential interplay between CBD’s anti-inflammatory and serotonergic properties, shedding light on the complex molecular mechanisms that underlie its therapeutic efficacy. The dual targeting of neuroinflammation and serotonin signaling provides a promising strategy for the treatment of SCZ, which has traditionally been treated with a limited focus on dopamine receptors [80]. This new insight could pave the way for the development of novel, more effective therapeutic approaches for patients suffering from SCZ. By concurrently dampening neuroinflammation (via cytokine suppression) and enhancing serotonin-mediated neuroprotection (via 5-HT1AR), CBD addresses both the “inflammatory storm” and synaptic dysfunction characteristic of SCZ. This dual mechanism offers a promising alternative to single-target therapies, particularly for treatment-resistant cases or early-phase interventions aimed at halting disease progression. Future studies should explore CBD’s synergies with existing antipsychotics to mitigate metabolic side effects while amplifying cognitive benefits-a critical unmet need in SCZ. management. Overall, the results obtained from our study contribute meaningful insights into the potential therapeutic mechanisms underlying the efficacy of CBD in treating SCZ. The utilization of a network pharmacology approach allowed for a comprehensive understanding of the multi-faceted effects of CBD on various biological pathways associated with the disorder. The observed anti-inflammatory properties of CBD and its impact on serotonin signaling provide further evidence of the intricate interplay between these mechanisms, shedding light on the potential synergistic effects of CBD’s anti-inflammatory and serotonergic properties in ameliorating symptoms of SCZ. Together, our findings support the therapeutic potential of CBD for SCZ by attenuating neuroinflammation, in part via 5-HT1AR-MAPK signaling. While our study advances understanding of CBD’s role in SCZ, several limitations warrant consideration. First, the exclusive focus on male mice limits generalizability to female populations and genetically diverse contexts. As sex differences in neuroimmune modulation and cannabinoid receptor activity have been well-documented, future studies should include both male and female subjects to explore potential sex-specific responses. For instance, estrogen-mediated modulation of neuroinflammatory processes may influence the therapeutic effects of CBD differently in males and females. Additionally, genetic factors could play a role in the variation of responses to CBD, as different mouse strains (e.g., DBA/2 mice, which have altered serotonin receptor density) may present divergent therapeutic outcomes. Investigating such genotype-dependent variations could offer valuable insights into how individual genetic backgrounds affect CBD’s efficacy. Moreover, the use of a single animal model (the ketamine-induced model) represents another limitation. While this model is widely used to study SCZ-like symptoms, it may not fully capture the complexity and heterogeneity of the disorder in humans. Future studies should consider employing additional preclinical models, such as those based on genetic or environmental stressors, to better mimic the broad spectrum of SCZ symptoms. Expanding to chronic neuroinflammatory models, such as prolonged LPS exposure or combinatorial stress-inflammatory challenges, could provide deeper insight into CBD’s potential for sustained anti-inflammatory effects and long-term neuroprotection. These chronic paradigms could clarify whether CBD has lasting therapeutic benefits and how it may influence disease progression over time. In addition, our study does not include causal mechanistic data to definitively link CBD’s effects to specific molecular pathways. While we identified potential pathways through network pharmacology and validated some of these using in vitro and in vivo models, we do not yet have direct causal evidence. Specifically, the 5HT1AR-MAPK signaling pathway appears to be involved in both the reduction of neuroinflammation and the improvement of behavior, but other potential pathways or cellular mechanisms that may also contribute to these effects remain to be fully characterized.Further experiments, such as pathway inhibition studies or time-course analyses, would provide more compelling evidence for the causal role of these pathways in CBD’s therapeutic effects. Another limitation is the relatively small sample size used in our behavioral assays (n = 5 per group), which may limit the statistical power and reliability of our findings. While this sample size is typical in preclinical research, particularly with more complex behaviors, we recognize that larger sample sizes are needed to strengthen the robustness and generalizability of the results. A more extensive sample size would improve statistical confidence and reduce the risk of Type I and Type II errors. Lastly, we acknowledge that we did not include a CBD-treated control group in this particular experiment, which represents a limitation. In future studies, we plan to incorporate a CBD-treated control group to better isolate the effects of CBD on social interaction, independent of ketamine-induced SCZ-like behaviors. This addition will allow for a more precise evaluation of CBD’s impact on social dysfunction, a key negative symptom of SCZ. By addressing this gap, we aim to provide a more comprehensive assessment of CBD’s therapeutic potential across the full spectrum of SCZ-like behaviors. Materials and Methods Network Pharmacology Analysis Cannabidiol-related Targets Prediction Target prediction of cannabidiol was carried out using four databases, including DrugBank (https://go.drugbank.com/) [81], SwissTargetPrediction (http://www.swisstargetprediction.ch/) [82], PharmMapper (http://www.lilab-ecust.cn/pharmmapper/) [83] and Search Tool for Interacting Chemicals (STITCH, http://stitch.embl.de/) [84]. In this present study, the screening criteria included a confidence score of ≥ 0.4. SCZ-Related Target Screening SCZ-related genes were acquired from five sources: GeneCards (https://www.geneca rds.org/) [85], Online Mendelian Inheritance in Man (OMIM, https://omim.org/) [86]. Therapeutic Target Database (TTD, https://db.idrblab.org/ttd/) [87], Pharmacogenomics Knowledge Base (PharmGKB, https://www.pharmgkb.org/) [88], and Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo) databases. The GeneCards, OMIM, TTD and PharmGKB platforms were searched using the keyword “schizophrenia”. Furthermore, R/Limma package and R package sva were selected SCZ-related genes from the GSE38484 (105 SCZ and 97 control) and GSE38481 (14 SCZ and 23 control) datasets. Differentially expressed genes were identified with |log2FC|> 0.2 and adjusted p-value < 0.05 as the threshold. Network Construction and Enrichment Analysis By intersecting the obtained cannabidiol-related targets with these genes that were considered potential targets of SCZ. Then, the acquired target genes were input in the Search Tool for the Retrieval of Interacting Genes (STRING, https://string-db.org/), setting the species to “Homo sapiens” to acquire a protein–protein interaction network, with a confidence score of 0.4. Furthermore, the Cytoscape tool [89] was employed to visualize and examine the relationships between the genes in the network. Meanwhile, the Cytoscape plugin Molecular Complex Detection (MCODE) was applied to analyze clustering modules in the network of cannabidiol-related target genes. In addition, Gene Ontology (GO) function enrichment analysis and Kyoto Encyclopedia of Genes and Genomes pathway (KEGG) pathway enrichment analysis were performed to illustrate the role of the potential targets in biological function and signal pathways. R packages, including Bioconductor clusterProfiler, Genome-wide annotation for Human (org.Hs.eg.db), enrichplot, Disease Ontology Semantic and Enrichment analysis (DOSE) and Grammar of Graphics plotting system (ggplot2) were used for GO and KEGG pathway analysis. Molecular Docking and Dynamics Simulation The protein structure (PDB ID: 8JT6) was obtained from the RCSB Protein Data Bank, and structural preparation, including water removal and hydrogen addition, was performed using PyMOL. The ligand structure was retrieved from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/). Blind docking was conducted using the CB-DOCK2 server (https://cadd.labshare.cn/cb-dock2/php/blinddock.php), which utilizes neural network-based cavity detection and Autodock Vina for docking [90]. The docking results were selected based on binding energy, followed by interaction force analysis and docking position assessment to validate binding stability through subsequent molecular dynamics simulations. Ligand-receptor interaction analysis was performed using the PLIP server (https://plip-tool.biotec.tu-dresden.de/plip-web), and the 3D ligand-receptor complex was visualized using PyMOL. The molecular dynamics (MD) simulations were performed using Gromacs 2023.3 software [91], starting from the molecular docking results of the ligand–protein complex as the initial structure. The ligand was described using the GAFF force field, while the protein was modeled with the AMBER protein force field [92, 93]. The system was prepared using the pdb2gmx tool to add hydrogen atoms and a truncated cubic TIP3P solvent box at a 10 Å distance [94], with Na +/Cl- ions added to balance the system's charge. Topology and parameter files for the simulation were generated accordingly. Energy minimization was performed using the mdrun command with the steepest descent method under a canonical ensemble (NVT) before starting the simulation. The simulation duration was 100 ns. Initially, the system was equilibrated at 310.15 K using NVT simulation for 100 ps, followed by a 100 ps NPT simulation to equilibrate the pressure to 1 bar using the Berendsen barostat. All hydrogen bonds were constrained using the LINCS algorithm, and a 2 fs integration step was used. Electrostatic interactions were calculated using the Particle-Mesh Ewald (PME) method with a cutoff value of 1.2 nm. Nonbonded interactions were truncated at 10 Å, with updates occurring every 10 steps. The trajectory was processed with periodic boundary conditions, followed by RMSD, RMSF, radius of gyration (Rg), and hydrogen bond analysis. Validation of CBD Preventing Neuroinflammation in BV2 Cells Induced by LPS To validate the predicted mechanisms of CBD against SCZ, the protective effects of CBD on neuroinflammation were verified using the LPS-induced inflammation BV2 cell model. Chemicals and Reagents Cannabidiol (purity 95%) and LPS (Escherichia coli serotype 055:B5) were purchased from Sigma-Aldrich, dissolved in Dimethyl sulfoxide (DMSO), and diluted in the Dulbecco's Modified Eagle Medium (DMEM). BV2 cell line was purchased from Procell Life Science& Technology Co, Ltd. (Wuhan, China). Primary antibodies 5-HT1A Receptor (5-HT1AR), p38 Mitogen-Activated Protein Kinase (p38 MAPK), Phosphorylated p38 Mitogen-Activated Protein Kinase (P-p38 MAPK), Extracellular Signal-Regulated Kinase 1/2 (ERK1/2), Phosphorylated Extracellular Signal-Regulated Kinase 1/2 (P-ERK1/2), Activator Protein 1 (AP-1), Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and anti-rabbit IgG horseradish conjugated secondary antibodies were purchased from Abcam. Ketamine hydrochloride was sourced from the Yunnan Provincial Public Security Department. It was converted into the appropriate ketamine dose, dissolved in physiological saline, and administered intraperitoneally (i.p.) at a volume of 0.1 ml per 10 g of body weight. Cannabidiol (98% purity) was obtained from Sigma-Aldrich (USA). Microglia Cell Culture BV2 cells were cultured in DMEM medium with 10% fetal bovine serum (FBS, Thermo Fisher Scientific, Waltham, MA, USA) and 1% penicillin–streptomycin (Thermo Fisher Scientific) at 37 °C with 5% CO2. BV2 cells are cultured until they reach a density of 70%−80%, at which point trypsin–EDTA is used for passaging, and passages 5 to 15 are utilized for subsequent experiments. Additionally, studies have shown that BV2 cells can be passaged up to 30 passages [95].The BV2 microglia was stimulated with LPS to mimic the inflammatory environment of the schizophrenic brain. Cell Viability by Cell Counting Kit-8 (CCK8) Assay Cell viability was determined by using the CCK8 assay. BV2 cells were seeded into 96-well plates and incubated overnight at 37 °C. On the following day, the cells were treated with different concentrations of CBD (0, 0.1, 0.5, 1, 5, 10,50 or 100 μM) for 24 h at 37 °C. Then 10 µL CCK8 was added to each well, incubated at 37 °C for 2 h. Absorbance at 450 nm was then measured to determine cell viability. Finally, following pretreatment with three different concentrations of CBD, the cells were stimulated with 1 µg/mL LPS for 24 h with a 4-h interval. After LPS stimulation, the cell was incubated with 10 µL CCK8 at 37 °C for 2 h and detected absorbance at 450 nm. Vehicle controls (0.1% DMSO for in vitro experiments; saline forin vivo) were included in all assays. Enzyme-Linked Immunosorbent Assay (ELISA) The neuroprotective effects of CBD against LPS-induced inflammation in BV2 cells were evaluated. The microglia were pretreated with CBD (5, 10 or 50 μM) for 4 h and stimulated with LPS (1 µg/mL) for 24 h. Subsequently, the cells were collected and centrifuged at 702× g for 5 min. The levels of Nitric Oxide (NO), Interleukin-1 beta (IL-1β), Interleukin-6 (IL-6) and Tumor Necrosis Factor alpha (TNF-α) in the supernatant using NO, IL-1β, IL-6 and TNF-α ELISA kit (NEOBIOSCIENCE, Shenzhen, China) according to the manufacturer's instructions. Western Blot Analysis The western blot assay was used to detected the protein levels of 5-HT1AR, p38 MAPK, p-p38 MAPK, ERK1/2, p-ERK1/2, and AP-1. After appropriate treatments, the cells were collected and the total proteins were extracted with radioimmunoprecipitation (RIPA) buffer containing 1 mM Phenylmethylsulfonyl fluoride (PMSF, Beyotime, Shanghai, China). According to the manufacturer’s protocol, the bicinchoninic acid (BCA) protein assay was selected to determine the protein concentrations (Beyotime, Shanghai, China). Briefly, an equal amount of 40 µg protein was loaded and analyzed by 12.5% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (EpiZyme, MA, USA) and transferred to a polyvinylidene fluoride membrane (PVDF membrane, Millipore, MA, USA). The size-cut membrane was blocked in TBST with 5% non-fat milk for 2 h at room temperature and then incubated with primary antibodies including: rabbit anti-5HT1A Receptor (1:1000 dilution; cat. no. ab85615, Abcam, MA, USA/cat. no. GTX104703, GeneTex, CA, USA), anti-p38 MAPK(1:1000 dilution; cat. no. 8960, Cell Signaling Technology, MA, USA), Phospho-p38 MAPK (Thr180/Tyr182) (1:1000 dilution; cat. no. 8960, Cell Signaling Technology, MA, USA), anti-ERK1/2(1:1000 dilution; cat. no. 4695 T, Cell Signaling Technology, MA, USA), Phospho-ERK1/2(Thr202/Tyr204) (1:1500 dilution; cat. no. 4370 T, Cell Signaling Technology, MA, USA), anti-AP-1(1:1000 dilution; cat. no. 9165 T, Cell Signaling Technology, MA, USA), GAPDH(1:2500 dilution; cat. no. ab9485, Abcam, MA, USA) and β-actin (1:20,000 dilution, cat. no. T0022, Affinity, OH, USA), overnight at 4 °C. After being washed three times with Tris-buffered saline with Tween (TBST), the membranes were incubated with anti-rabbit IgG secondary antibodies (dilution 1:5000) at room temperature for 2 h on the following day. Finally, the protein signals were visualized by a chemiluminescence Enhanced Chemiluminescence (ECL) assay kit and captured using a ChemiScope 6000Touch imaging system (CLINX, Shanghai, China). All protein expression levels were normalized to GAPDH/β-actin. cAMP Assay Intracellular cAMP levels were determined using a cAMP ELISA Kit (Elabscience®, cat. no. E-EL-0056) according to the manufacturer’s instructions. BV2 cells were lysed after treatment, and the supernatants were used for cAMP quantification. In brief, samples or standards were added to antibody-coated plates followed by incubation with HRP-conjugated reagents. After substrate development and reaction termination, absorbance was measured at 450 nm. All measurements were conducted in biological triplicates. Animal Study Only male mice were used because epidemiological studies indicate a higher incidence and earlier onset of schizophrenia in males than in females [96, 97]. Male C57BL/6 N mice, aged six weeks, were supplied by Zhejiang Vital River Laboratory Animal Technology Co., Ltd. (Zhejiang, China). The animals were housed in groups for one week under controlled conditions, including a temperature of 23 ± 2℃, a 12-h light–dark cycle, 50 ± 5% humidity, with free access to water and standard mouse chow. All experimental procedures followed the guidelines outlined in the National Institutes of Health Guide for the Care and Use of Laboratory Animals. This study was approved by the Medical Ethics Committee of North Sichuan Medical College (2024089). The experimental design was based on the findings of our previous study [24], which demonstrated that ketamine (25 mg/kg, i.p., four times daily for 12 days) could be used to establish a mouse model of SCZ. After the 12-day treatment period, the mice were administered either a vehicle or cannabidiol (CBD) at a dose of 10 mg/kg, i.p., once daily for 5 consecutive days. The dose of CBD (10 mg/kg) was selected based on its demonstrated efficacy in mitigating ketamine-related behavioral and neurochemical alterations without inducing sedation or toxicity. For instance, Poulia et al. [98] reported that chronic CBD administration (10 mg/kg) reversed ketamine-induced hyperactivity and restored glutamatergic signaling in rats. Similarly, Brakatselos et al. [41] further demonstrated that this dose prolonged ketamine’s motor-stimulatory effects while rescuing neuroplasticity markers. These studies not only validate the 10 mg/kg dose as effective in modulating ketamine-driven phenotypes but also provide a mechanistic rationale for its use in our model. To evaluate CBD’s behavioral impact, we employed standardized tests, including open field (OFT), elevated plus maze (EPM), and Y-maze, and sociability and social memory as detailed in our earlier methodology [24]. The EPM test, in particular, was chosen to assess anxiety-like behaviors [99], as anxiety is commonly observed in ketamine-induced models. Group size was set at n = 5 per group, consistent with sample sizes commonly used in comparable ketamine-CBD studies [100–102] and with the expected effect sizes for our primary endpoints. Plasma samples were collected under anesthesia on the second day following the behavioral tests, centrifuged, and stored at −80 °C until analysis. Cytokine separation was performed using the Meso Scale Discovery kit (Meso Scale Diagnostics, Rockville, MD, USA) following the manufacturer’s instructions. Inflammatory biomarker levels (IFN-γ, TNF-α, IL-1α, IL-2, IL-5, IL-10, and IL-12p70) were measured using the MESOTM QuickPlex SQ 120 system (Meso Scale Diagnostics, Rockville, MD, USA). Data were analyzed with MSD Discovery Workbench 4.0 software (Meso Scale Diagnostics). The detection limit for the inflammatory cytokines was 0.01 pg/mL, and all standards and plasma samples were tested in duplicate. The inclusion of IL-6 in vitro BV2 cell experiments and IL-5 in vivo plasma analyses was guided by their distinct roles in neuroinflammatory and systemic inflammatory cascades, respectively. Specifically, IL-6 is a well-established mediator of microglial activation and neuroinflammation in BV2 models [103, 104], whereas IL5, though less studied in SCZ, reflects broader Th2-mediated immune responses in systemic inflammation [105, 106]. This dual focus aligns with our aim to dissect CBD’s effects across localized (CNS) and peripheral inflammatory pathways. Brain tissues were carefully dissected and collected, focusing on regions of hippocampus. These regions were chosen due to their known involvement in cognitive and emotional processing, which are relevant to schizophrenia-like behaviors. The collected brain tissues were then immediately stored at −80 °C until further analysis. To measure neuroinflammation, the brain tissue was weighted and homogenized in with 10 volumes of cold PBS. After homogenization, the samples were centrifuged at 12,000 × g for 30 min at 4 °C to collect the supernatant. The protein concentration of the supernatants was determined using a BCA protein assay kit (Beyotime, Shanghai, China). Levels of the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α in the brain tissue were quantified using enzyme-linked immunosorbent assay (ELISA) kits (NEOBIOSCIENCE, Shenzhen, China) according to the manufacturer’s instructions. The cytokine concentrations were normalized to total protein content (pg/mg protein) and expressed as means ± SD for each experimental group. Statistical Analysis All data are expressed as mean ± standard deviation (SD). Analyses and graphs were performed in GraphPad Prism 9 (GraphPad Software, San Diego, CA, USA). Before running ANOVA, data normality was assessed with the Shapiro–Wilk test and homogeneity of variance with Levene’s test. Outlier analysis was conducted on each dataset using the Grubbs’ test (α = 0.05); no outliers were detected, and therefore no observations were removed. Group comparisons were conducted using one-way ANOVA (two-tailed). Unless otherwise noted, post hoc tests were: Dunnett’s multiple comparisons test for planned comparisons to a control (used for Figs. 3 and 4, 7, 8, 9 as indicated), and Tukey’s multiple comparisons test for all pairwise comparisons in Fig. 6. The significance threshold was p < 0.05. Here, n denotes biological replicates (independent mice or independent cultures); technical replicates, when present, were averaged within each biological replicate. Conclusion In conclusion, our study makes significant contributions to understanding the therapeutic mechanisms underlying CBD’s efficacy in treating SCZ. The use of a network pharmacology approach has provided a comprehensive understanding of CBD’s multi-faceted effects on various biological pathways associated with the disorder. CBD may advance SCZ treatment by targeting neuroinflammation through mechanisms that include, but are not limited to, modulation of 5-HT1AR-MAPK signaling. The integration of behavioral outcomes and cytokine modulation provides a compelling picture of CBD’s therapeutic potential, suggesting that its anti-inflammatory and serotonergic properties could synergistically improve both cognitive and psychotic symptoms in SCZ. This dual action is particularly relevant given the limitations of current antipsychotic medications, which predominantly target dopaminergic pathways but fail to address the neuroinflammatory component of SCZ. By combining network pharmacology with in vivo and in vitro validation, our research provides a holistic perspective on CBD’s therapeutic mechanisms, setting the groundwork for future studies on its role as a complementary therapy in SCZ. Future research should focus on exploring the long-term effects of CBD, particularly in combination with conventional antipsychotics, to determine whether it can enhance therapeutic outcomes or mitigate side effects. Additionally, clinical studies investigating CBD’s effects on specific SCZ subtypes or on treatment-resistant cases could further elucidate its potential for personalized treatment strategies. Supplementary Information Below is the link to the electronic supplementary material. Supplementary file1 (XLSX 11 KB) Supplementary file2 (PDF 517 KB) Acknowledgements The authors sincerely thank Wensong Zhao and Ping Fang from the Yunnan Provincial Public Security Department for their expert assistance. We also wish to express our gratitude to Dr. Rongchuan Su for his generous support with the technical work and bioinformatics analysis involved in this study. Author Contributions Author Contributions: Conceptualization, Ying Wei and Linchuan Liao; methodology, Ying Wei and Xiang Liu; software, Xiang Liu; validation, Ying Wei, Xiang Liu, and Shijun Lin; formal analysis, Ying Wei; investigation, Ying Wei and Shijun Lin; resources, Zhiwei Jia; data curation, Lin Liu; writing-original draft preparation, Ying Wei and Shijun Lin; writing-review and editing, Ying Wei, Xiang Liu, and Xue Mei; visualization, Zhiwei Jia and Baiqiang Wang; supervision, Linchuan Liao and Xue Mei; project administration, Linchuan Liao; funding acquisition, Ying Wei, Lin Liu, Linchuan Liao and Xue Mei. All authors have read and agreed to the published version of the manuscript. Funding Funding from the Scientific Startup Foundation for Doctors of North Sichuan Medical College to Ying Wei (CBY23-QDA03), Xue Mei (CBY23-QDA11); Sichuan Provincial Natural Science Foundation to Linchuan Liao (2024NSFSC0531); the Nanchong Science and Technology Bureau (No. 22SXQT0162) and the Famous and Senior Traditional Chinese Medicine Physicians’ Medical Records Research Center (YAZX21-YB-34) awarded to Lin Liu. Data Availability The data supporting the reported results of this study are available from the corresponding author upon reasonable request. Declarations Institutional Review Board Statement The animal study protocol was approved by the Institutional Review Board of North Sichuan Medical College (Protocol No.: 2024089; Approval Date: 20240712). All experimental procedures followed the guidelines outlined in the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Clinical trial number Not applicable. Conflicts of interest The authors declare no competing interests. Footnotes Ying Wei is the first author of this paper. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Linchuan Liao, Email: linchuanliao@scu.edu.cn. Xue Mei, Email: 86121910@qq.com. References Associated Data Supplementary Materials Supplementary file1 (XLSX 11 KB) Supplementary file2 (PDF 517 KB) Data Availability Statement The data supporting the reported results of this study are available from the corresponding author upon reasonable request.